MX9803706A - Metodo para transferir genes dentro de celulas objetivo, con retrovirus. - Google Patents

Metodo para transferir genes dentro de celulas objetivo, con retrovirus.

Info

Publication number
MX9803706A
MX9803706A MX9803706A MX9803706A MX9803706A MX 9803706 A MX9803706 A MX 9803706A MX 9803706 A MX9803706 A MX 9803706A MX 9803706 A MX9803706 A MX 9803706A MX 9803706 A MX9803706 A MX 9803706A
Authority
MX
Mexico
Prior art keywords
retrovirus
target cells
gene introduction
effective amount
functional substance
Prior art date
Application number
MX9803706A
Other languages
English (en)
Inventor
Kiyozo Asada
Takashi Uemori
Takashi Ueno
Nobuto Koyama
Kimikazu Hashino
Ikunoshin Kato
Original Assignee
Takara Shuzo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Shuzo Co filed Critical Takara Shuzo Co
Publication of MX9803706A publication Critical patent/MX9803706A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se da a conocer un método para aumentar la eficiencia de la transferencia de genes en células objetivo, con un retrovirus. En este método, las células objetivo son infectadas con el retrovirus, en la presencia de o una mezcla de una cantidad efectiva de un material funciona, que tiene dominios de union de retrovirus, y una cantidad efectiva de otro material funcional, que tiene dominios de union de las células objetivo o una cantidad efectiva de un material funcional, que tiene estos dominios de union en la misma molécula. Los materiales funcionales se pueden usar sin inmovilizacion con inmovilizados sobre globulos. Este método es util, por ejemplo, en la terapia de genes.
MX9803706A 1995-11-13 1998-05-11 Metodo para transferir genes dentro de celulas objetivo, con retrovirus. MX9803706A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29438295 1995-11-13
JP5184796 1996-03-08

Publications (1)

Publication Number Publication Date
MX9803706A true MX9803706A (es) 1998-09-30

Family

ID=26392431

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803706A MX9803706A (es) 1995-11-13 1998-05-11 Metodo para transferir genes dentro de celulas objetivo, con retrovirus.

Country Status (13)

Country Link
US (5) US6472204B1 (es)
EP (1) EP0870839B1 (es)
JP (1) JP3343357B2 (es)
KR (2) KR100353115B1 (es)
CN (1) CN100390290C (es)
AT (1) ATE325884T1 (es)
AU (1) AU709831B2 (es)
CA (1) CA2235629A1 (es)
DE (1) DE69636122T2 (es)
EA (3) EA003204B1 (es)
ES (1) ES2259182T3 (es)
MX (1) MX9803706A (es)
WO (1) WO1997018318A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083979B1 (en) * 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
DE69636124T2 (de) * 1995-09-29 2006-12-21 Indiana University Research And Technology Corp., Bloomington Verfahren zum verbesserten virusvermittelten dns-transfer unter verwendung von molekülen mit virus- und zellbindenden domänen
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
JP2001523468A (ja) * 1997-11-14 2001-11-27 セダーシナイ メディカル センター トランスジェニック種の産生のための雄性生殖細胞のトランスフェクションおよび移入
EP1094114B1 (en) * 1998-07-01 2007-01-03 Takara Bio Inc. Gene transfer methods
AU1458200A (en) * 1998-10-31 2000-05-22 University Of Medicine And Dentistry Of New Jersey A myeloid precursor cell useful for gene therapy and for modulation of immune responses
KR100674140B1 (ko) * 1999-03-23 2007-01-26 다카라 바이오 가부시키가이샤 유전자 치료제
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
AU5958000A (en) * 1999-07-08 2001-01-30 Connie Jean Eaves Method to improve viral infection
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
WO2002018550A1 (en) 2000-08-25 2002-03-07 The General Hospital Corporation Selective precipitation of viruses
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
DE60232149D1 (de) * 2001-06-20 2009-06-10 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
ATE429486T1 (de) 2001-08-15 2009-05-15 Takara Bio Inc Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
ATE384785T1 (de) * 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
TWI334442B (en) * 2002-03-25 2010-12-11 Takara Bio Inc Process for producing cytotoxic lymphocyte
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
DK1623023T3 (da) 2003-05-09 2009-03-02 Crucell Holland Bv Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra
ATE469920T1 (de) * 2003-05-23 2010-06-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
FR2857598A1 (fr) * 2003-07-18 2005-01-21 Inst Nat Sante Rech Med Composes anti-angiogeniques, composition pharmaceutique les comprenant, et leur utilisation
KR101331746B1 (ko) 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
JP5546716B2 (ja) * 2004-09-29 2014-07-09 タカラバイオ株式会社 レトロウイルスベクター産生用細胞
EP1847596B1 (en) 2005-02-07 2012-05-23 Takara Bio, Inc. Method of retrovirus storage
EP1892294A4 (en) 2005-06-15 2010-04-14 Takara Bio Inc METHOD OF TRANSFERRING GENES IN FAT CELLS OR PRECURSOR FAT CELLS
WO2007012144A1 (en) * 2005-07-29 2007-02-01 Australian Stem Cell Centre Limited Compositions and methods for growth of pluripotent cells
US8889844B2 (en) 2005-08-16 2014-11-18 Takara Bio Inc. Nucleic acid for treatment or prevention of immunodeficiency virus infection
KR101279172B1 (ko) 2005-08-17 2013-06-27 다카라 바이오 가부시키가이샤 림프구의 제조 방법
JP4741906B2 (ja) * 2005-08-31 2011-08-10 タカラバイオ株式会社 リンパ球の製造方法
EP1939278A4 (en) 2005-09-30 2009-06-03 Takara Bio Inc METHOD FOR PRODUCING A T CELL POPULATION
WO2007142300A1 (ja) 2006-06-09 2007-12-13 Takara Bio Inc. リンパ球の製造方法
WO2008133137A1 (ja) 2007-04-20 2008-11-06 Takara Bio Inc. 遺伝子治療のためのベクター
WO2009119793A1 (ja) 2008-03-27 2009-10-01 タカラバイオ株式会社 遺伝子導入細胞の製造方法
CN102144027B (zh) 2008-07-07 2016-04-06 宝生物工程株式会社 生产多能干细胞的方法
WO2010080032A2 (en) * 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
EP2471901A4 (en) 2009-08-25 2013-06-26 Takara Bio Inc PROCESS FOR PRODUCING T-CELL POPULATION IN THE PRESENCE OF RETINOIC ACID
KR101679602B1 (ko) 2009-09-11 2016-11-25 다카라 바이오 가부시키가이샤 내추럴킬러 세포의 제조방법
CN102725308A (zh) * 2009-11-30 2012-10-10 昆士兰技术大学 纤连蛋白:生长因子嵌合物
US9228206B2 (en) 2010-06-30 2016-01-05 Takara Bio Inc. Method for gene transfer
US8841126B2 (en) 2010-06-30 2014-09-23 Takara Bio Inc. Method for gene transfer
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
CN109790536A (zh) 2016-07-29 2019-05-21 宝生物工程株式会社 用于干细胞产生的纤连蛋白片段
WO2018053463A1 (en) 2016-09-19 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
CN108103045B (zh) * 2016-11-25 2022-10-04 丰益(上海)生物技术研发中心有限公司 脂肪酶及其应用
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
EP3397998A4 (en) 2017-02-22 2019-04-17 Lumus Ltd. OPTICAL LIGHT GUIDE ASSEMBLY
JP7173994B2 (ja) 2018-01-25 2022-11-17 タカラバイオ株式会社 リンパ球の製造方法
US10983264B2 (en) 2019-01-24 2021-04-20 Lumus Ltd. Optical systems including light-guide optical elements with two-dimensional expansion
KR20220119479A (ko) * 2019-12-30 2022-08-29 생-고뱅 퍼포먼스 플라스틱스 코포레이션 세포 형질 도입을 위한 컨테이너 및 방법
CN113444167B (zh) * 2021-07-15 2022-09-30 陕西巨子生物技术有限公司 重组人胶原蛋白多肽及其应用
CN114634984A (zh) * 2022-02-02 2022-06-17 复旦大学 一种脑胶质瘤生物标记物mlkl基因及其应用
WO2023213969A1 (en) * 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
CN114965839A (zh) * 2022-05-11 2022-08-30 朗肽生物制药股份有限公司 人碱性成纤维细胞生长因子的肽图分析方法
US20240167019A1 (en) * 2022-11-18 2024-05-23 Saint-Gobain Performance Plastics Corporation Aptamers, containers and methods for cell transduction
CN117603343B (zh) * 2024-01-19 2024-04-26 四川大学 阻断bFGF的胶原来源天然短肽及应用
CN117645664A (zh) * 2024-01-29 2024-03-05 英特菲尔(成都)生物制品有限责任公司 重组人纤连蛋白标准品及其制备方法、鉴定方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US5026839A (en) 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
JP2770926B2 (ja) * 1985-12-17 1998-07-02 サイナーゲン インコーポレーテッド 毛管内皮細胞プロテアーゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5492890A (en) 1990-12-03 1996-02-20 The Scripps Research Institute Polypeptides for promoting cell attachment
DE4110409C2 (de) * 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
CH685803A5 (fr) * 1992-06-09 1995-10-13 Francis Verdan Bâton d'alun fixé dans un étui.
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5686278A (en) 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
JPH1029952A (ja) 1996-07-16 1998-02-03 Takara Shuzo Co Ltd ヒト免疫不全ウイルス感染の制御用組成物および制御方法

Also Published As

Publication number Publication date
JP3343357B2 (ja) 2002-11-11
CN1207774A (zh) 1999-02-10
KR19990067446A (ko) 1999-08-16
EP0870839A1 (en) 1998-10-14
EA200001110A1 (ru) 2001-06-25
US7790849B2 (en) 2010-09-07
US20090209730A1 (en) 2009-08-20
KR100353115B1 (ko) 2003-01-06
EP0870839B1 (en) 2006-05-10
EA003204B1 (ru) 2003-02-27
US6472204B1 (en) 2002-10-29
AU7505896A (en) 1997-06-05
ATE325884T1 (de) 2006-06-15
WO1997018318A1 (en) 1997-05-22
AU709831B2 (en) 1999-09-09
EA003195B1 (ru) 2003-02-27
EP0870839A4 (en) 2000-01-19
US20060030046A1 (en) 2006-02-09
EA004928B1 (ru) 2004-10-28
KR100395420B1 (ko) 2003-08-21
DE69636122D1 (de) 2006-06-14
US6426042B1 (en) 2002-07-30
DE69636122T2 (de) 2006-12-07
EA200200837A1 (ru) 2002-12-26
EA199800369A1 (ru) 1998-12-24
ES2259182T3 (es) 2006-09-16
US20030087437A1 (en) 2003-05-08
CA2235629A1 (en) 1997-05-22
US6949623B2 (en) 2005-09-27
US7446170B2 (en) 2008-11-04
CN100390290C (zh) 2008-05-28

Similar Documents

Publication Publication Date Title
MX9803706A (es) Metodo para transferir genes dentro de celulas objetivo, con retrovirus.
CA2163781A1 (en) Method and Apparatus for Conducting an Array of Chemical Reactions on a Support Surface
NO992167D0 (no) Preparater og fremgangsmÕter for immobilisering av nukleinsyrer til faste bµrere
BG101103A (en) Mammalian telomerase
IL128003A (en) MULTISPECIFIC BINDING MOLECULES COMPRISING A BINDING DETERMINANT WHICH BINDS AN FCalpha RECEPTOR
NZ331189A (en) Method of detection of influenza virus using neuraminidase binders
MX9603532A (es) Sistema de suministro de acido nucleico, metodo de sintesis y sus usos.
WO2000044389A3 (fr) Procede de preparation de vesicules membranaires
AU1884392A (en) Peptide nucleic acids
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
EP0861262A4 (en) GROUPS FOR CATCHING NUCLEIC ACIDS
AU6058094A (en) Internal controls for iosthermal nucleic acid amplification reactions
AU2284697A (en) Fusogenic liposomes
AU1530401A (en) Security system
WO1996001614A3 (en) Rna component of telomerase
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
AU3143897A (en) Oligonucleotides which specifically bind retroviral nucleocapsid proteins
AU3677095A (en) Radioactive phosphorous labeling of proteins for targeted radiotherapy
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
IE64781B1 (en) Immunoglobulin conjugates
CA2038577A1 (en) Utilization and delivery of enzymes
NZ337924A (en) Site-specific drug delivery compounds comprising an anchoring moiety, a linking group and a drug
ES2185024T3 (es) Procedimiento que permite mejorar el rendimiento de un reactivo inmunologico en un dosificado inmunologico.